MarketPulse

Parkinson's disease

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Serina Therapeutics to Showcase POZ Platform at Roth Conference

Clinical-stage biotech Serina Therapeutics will present at 38th Annual Roth Conference on March 24, 2026, highlighting its proprietary POZ Platform technology and pipeline.
PFESERclinical-stage biotechParkinson's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Gain Therapeutics to Showcase Parkinson's Drug Progress at Major Medical Conferences

Gain Therapeutics will present Phase 1b data for Parkinson's treatment GT-02287 at major conferences, with CEO appearing at ROTH Conference on March 23, 2026.
GANXPhase 2 clinical trialParkinson's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference

Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Supernus to Present at Three Major Healthcare Conferences in March

Supernus Pharmaceuticals will present at three major healthcare conferences in March 2026, updating investors on strategic initiatives and operational progress.
SUPNinvestor conferencebiopharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Serina Therapeutics

Serina Therapeutics Advances SER-252 Development With First Phase 1b Enrollee

Serina Therapeutics enrolls first patient in Phase 1b trial for SER-252, an apomorphine-based Parkinson's treatment. FDA alignment on regulatory pathway supports streamlined development timeline.
SERFDA clearancePhase 1b trial